Literature DB >> 16061346

Differences in dissolution behavior in a phagolysosomal simulant fluid for single-constituent and multi-constituent materials associated with beryllium sensitization and chronic beryllium disease.

Aleksandr B Stefaniak1, Gregory A Day, Mark D Hoover, Patrick N Breysse, Ronald C Scripsick.   

Abstract

Particle dissolution within macrophage phagolysosomes is hypothesized to be an important source of dissolved beryllium for input to the cell-mediated immune reaction associated with development of beryllium sensitization and chronic beryllium disease (CBD). To better understand the dissolution of beryllium materials associated with elevated prevalence of sensitization and CBD, single-constituent (beryllium oxide (BeO) particles sampled from a screener operation, finished product BeO powder, finish product beryllium metal powder) and multi-constituent (particles sampled from an arc furnace during processing of copper-beryllium alloy) aerosol materials were studied. Dissolution rates were measured using phagolysosomal simulant fluid (PSF) in a static dissolution technique and then normalized to measured values of specific surface area to calculate a chemical dissolution rate constant (k) for each material. Values of k, in g/(cm2 day), for screener BeO particles (1.3 +/- 1.9 x 10(-8)) and for BeO powder (1.1 +/- 0.5 x 10(-8)) were similar (p = 0.45). The value of k observed for beryllium metal powder (1.1 +/- 1.4 x 10(-7)) was significantly greater than observed for the BeO materials (p < 0.0003). For arc furnace particles, k (1.6 +/- 0.6 x 10(-7)) was significantly greater than observed for the BeO materials (p < 0.00001), despite the fact that the chemical form of beryllium in the aerosol was BeO. These results suggest that dissolution of beryllium differs among physicochemical forms of beryllium and direct measurement of dissolution is needed for multi-constituent aerosol. Additional studies of the dissolution behavior of beryllium materials in a variety of mixture configurations will aid in developing exposure-response models to improve understanding of the risk of beryllium sensitization and CBD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061346     DOI: 10.1016/j.tiv.2005.06.031

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  6 in total

1.  Release of beryllium from mineral ores in artificial lung and skin surface fluids.

Authors:  Matthew G Duling; Aleksandr B Stefaniak; Robert B Lawrence; Steve J Chipera; M Abbas Virji
Journal:  Environ Geochem Health       Date:  2011-08-25       Impact factor: 4.609

2.  Pluronic F108 coating decreases the lung fibrosis potential of multiwall carbon nanotubes by reducing lysosomal injury.

Authors:  Xiang Wang; Tian Xia; Matthew C Duch; Zhaoxia Ji; Haiyuan Zhang; Ruibin Li; Bingbing Sun; Sijie Lin; Huan Meng; Yu-Pei Liao; Meiying Wang; Tze-Bin Song; Yang Yang; Mark C Hersam; André E Nel
Journal:  Nano Lett       Date:  2012-05-04       Impact factor: 11.189

Review 3.  Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.

Authors:  Amy S McKee; Shaikh M Atif; Michael T Falta; Andrew P Fontenot
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

4.  Behavior of potentially toxic elements from stoker-boiler fly ash in Interior Alaska: paired batch leaching and solid-phase characterization.

Authors:  Kyle P Milke; Kiana L Mitchell; Sarah M Hayes; Carlin J Green; Jennifer J Guerard
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-23       Impact factor: 5.190

Review 5.  Dissolution and biodurability: Important parameters needed for risk assessment of nanomaterials.

Authors:  Wells Utembe; Kariska Potgieter; Aleksandr Byron Stefaniak; Mary Gulumian
Journal:  Part Fibre Toxicol       Date:  2015-04-28       Impact factor: 9.400

Review 6.  A reconsideration of acute Beryllium disease.

Authors:  Kristin J Cummings; Aleksandr B Stefaniak; M Abbas Virji; Kathleen Kreiss
Journal:  Environ Health Perspect       Date:  2009-04-28       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.